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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective is to evaluate the efficacy and safety of fiber and bulking agents for the treatment of chronic constipation.
B A C K G R O U N D
Description of the condition
Constipation is among the most common gastrointestinal disor-
ders and a major public health problem (Anderson 2000). It is es-
timated that about 15% of adult population in western countries
suffer from constipation. The overall prevalence inNorth America
ranges from 4% to 18% with predominance among females. It
has been shown that constipation affects 5% of males and 15% of
female population (Talley 1999). The etiology of constipation re-
mains largely unknown. The variety of symptoms and risk factors
associated with constipation suggest that its etiology is likely to
be multifactorial. Although epidemiologic studies cannot estab-
lish etiologic relationships, consistent epidemiologic distributions
may suggest potential causative risk factors. Constipation does not
have one consistently used definition. When using the term the
lay public or health care professional may be referring to several
difficult to quantify variables: bowel movement frequency, stool
size or consistency, and symptoms such as a feeling of incomplete
evacuation. Stool frequency is often used to describe constipation
however using stool frequency to define constipation is not well
established .
The Rome criteria have been applied to clinical practice to identify
patients with constipation. TheRome III criteria define functional
constipation as a complex of at least two symptoms for the last 3
months with symptom onset at least 6 months prior to diagnosis.
These symptoms include infrequent bowel movements (less than
three per week), straining, lumpy or hard stools or a subjective
sensation of incomplete bowel evacuation or anorectal obstruction
or blockage, or manual maneuvers to enable defecation during at
least 25% of bowel movements (Longstreth 2006).
Constipation may be associated with a number of different dis-
eases or conditions. The known etiologies of constipation include
mechanical obstruction, metabolic disturbances, neurologic dis-
orders, and medication adverse effects. A large proportion of pa-
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tients with constipation do not have a known cause and suffer
from idiopathic or primary constipation. Primary constipation is
further classified into normal transit, slow transit and dyssyner-
gic constipation. Secondary constipation may be associated with
endocrine, metabolic, or neurologic diseases. It is also commonly
associated with chronic laxative use and medication such as opioid
analgesics, ferrous compounds and psychoactive drugs (Bassotti
2004).
Untreated chronic constipation can have serious medical conse-
quences. Studies have reported that constipation can lead to pu-
dendal nerve damage, resulting in fecal incontinence and rectal
prolapse. Chronic constipation has also been associated with uri-
nary tract infections and haemorrhoids (Mostafa 2003). A study
conducted on more than 100,000 patients revealed that patients
with chronic constipation were 5 times more likely to develop in-
testinal impaction and anal fissures (Singh 2005).
Chronic constipation poses difficulties in performing activities of
daily living, increased medical cost, reduced productivity at work
and ultimately reduces the health related quality of life (Singh
2007; Dennison 2005). Chronic constipation accounts for 13.7
million days of restricted activity across the whole population of
the United States (Dennison 2005). Another study reported that
the average cost of diagnosing a patient with chronic constipation
in a tertiary care setting approached to USD 2752 per patient
(Rantis 1997). A prospective study by Nyrop et al demonstrated
that the mean annual direct health care costs for treatment of
chronic constipation were approximately USD 7522 per patient
(Nyrop 2007).
Description of the intervention
Management of normal and slow transit chronic constipation in-
cludes patient education, lifestyle modification (increase exercise,
hydration), behavior modification, dietary changes (dietary fiber),
and bulk laxative therapy (psyllium or methylcellulose). There is
a dose response between fiber intake, water intake, and fecal out-
put. The recommended amount of dietary fiber is 20 to 35 g/day
(Marlett 2002). However, fiber may increase bloating, distention
and flatulence leading to poor compliance (estimated to be as low
as 50%). Bulk forming laxatives include psyllium seed, methylcel-
lulose, and calcium polycarbophil.
How the intervention might work
Bulk forming laxatives are natural or synthetic polysaccharides
or cellulose derivatives that primarily exert their laxative effect
by absorbing water and increasing fecal mass. These laxatives are
effective in increasing the frequency and softening the consistency
of stool with a minimum of adverse effects. Fiber and bulking
agents including bran,methylcellulose, calciumpolycarbophil and
psyllium are commonly used laxatives (Brandt 2005). Psyllium is
a soluble fiber. It absorbs water in the intestine to form a viscous
liquid which promotes peristalsis and reduce transit time. The
daily recommended dose for constipation in adults is 10 to 15
grams per day in divided doses (Johanson 2007). The onset of
action ranges from 12 to 72 hours. Reported adverse effects of
psyllium include: abdominal bloating, flatulence and cramps (
Gillespie 1992; Uehleke 2008; Wald 2008). The laxative effect of
wheat bran has been attributed to stimulation of bacterial growth
and to retention of water by the fiber matrix. Methylcellulose
absorbs water and expands in the intestine (known as peristalsis)
which usually results in a bowel movement within 12 to 24 hours.
Calcium polycarbophil also increases the bulk in stool, an effect
that helps to cause movement of the intestines. It also works by
increasing the amount of water in the stool, making the stool softer
and easier to pass (Eherer 1993).
Why it is important to do this review
Chronic constipation is often under treated as many people per-
ceive it as a temporary and personal problem that requires nomed-
ical attention. A random population-based survey in the United
States indicates that only 26% of the patients seek medical care
for constipation (Stewart 1999). However, many studies have re-
ported a high rate of compliance to fiber bulking agents (Levin
1990; Ramkumar 2005; Johanson 2007) compared to other syn-
thetic drug treatment regimens, as the desire to take a natural sup-
plement that is relatively cheap and easily available is appealing
for patients.
A systematic review of the efficacy and safety of fiber and bulk-
ing agents for the treatment of chronic constipation is required to
evaluate all available evidence based information about this com-
monly used natural product.
O B J E C T I V E S
The primary objective is to evaluate the efficacy and safety of fiber
and bulking agents for the treatment of chronic constipation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of fiber or bulking agent treatment
for chronic constipation will be considered for inclusion.
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Types of participants
Subjects of any age with symptoms of chronic constipation as
defined by the included studies will be considered for inclusion.
Types of interventions
Interventions that involve fiber or bulking agents for the treatment
of chronic constipation compared to placebo or any other active
treatment will be considered for inclusion.
Types of outcome measures
Primary outcomes
The primary outcomes will include:
• The proportion of patients with improvement in stool
frequency as defined by the included studies; and
• The proportion of patients with global improvement in
symptoms.
Secondary outcomes
Secondary outcomes will include:
• The proportion of patients experiencing three or more
spontaneous bowel movements per week;
• Proportion of patients achieving bowel evacuation at
defecation;
• Proportion of patients with bowel movements of normal
consistency;
• Proportion of patients with relief of abdominal pain;
• Quality of life; and
• Adverse events including: the proportion of patients who
experienced any adverse event, serious adverse events, and
withdrawal due to adverse events.
Search methods for identification of studies
We will identify all relevant trials regardless of language or publi-
cation status (published, unpublished, in press, and in progress).
Electronic searches
The following electronic databases will be searched irrespective
of language and publication status. Searches will be restricted to
human participants.
• The Central Register of Controlled Trials (CENTRAL)The
Cochrane Library
• MEDLINE from 1966 to January 2012
• EMBASE from 1980 to January 2012
• CINAHL from 1982 to January 2012
• LILIACS from 1985 to January 2012
The search terms will be combined with the highly sensitive search
strategy through MEDLINE and CENTRAL. The search terms
are as follows.
Mesh Subject Heading:
#1 exp constipation/all subheadings
#2 exp bulk forming agents /all subheadings
#3 Psyllium/ all subheadings
# 4 ispagula or ispaghula
# 5 Methylcellulose or celevac
# 6 Bran or trifyba
# 7 Psyllium & laxative
# 8 Psyllium & bulking agent
# 9 Isphagulla
# 10 Methylcellulose & laxative
# 11 Methylcellulose & Bulking agent
# 12 Methylcellulose & chronic constipation
# 13 Bran & laxative
# 14 Bran & bulking agent
# 15 Bran & chronic constipation
Text word terms/synonyms
#1 bowel function.tw.
#2 bowel habit.tw.
#3 bowel movement.tw.
#4 bowel symptom.tw.
#5 bowel motility.tw.
#6 constipation.tw.
Wewill also search databases such as, Biological Abstracts andWeb
of Science. We will search for ongoing trials on : ’CurrentCon-
trolled Trials’ registered at (www.controlled-trials.com - with links
to other databases of ongoing trials) and ClinicalTrials.gov (http:
//clinicaltrials.gov/). If additional key words of relevance are de-
tected during any of the electronic or other searches wewill modify
the electronic search. All duplicate studies will be removed.
Searching other resources
Conference Proceedings for Digestive Disease Week (DDW)
and United European Gastroentrology Week (UEGW) will
be searched. The European Crohn’s and Colitis Organisation
(ECCO) conference abstract database and the IBD/FBD group
specialized trials register will also be searched.
We will not impose any language or publication restrictions. We
will also search related conference proceedings for relevant ab-
stracts. Moreover, we will contact organisations and researchers in
the field and pharmaceutical companies for information on un-
published and ongoing trials. We will also check the reference lists
of all trials identified by the above methods for additional studies.
Data collection and analysis
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Selection of studies
Three review authors (KN, BA, SA) will independently assess all
the potential studies identified as a result of the search strategy for
inclusion based on the inclusion criteria described above. We will
resolve any disagreement through discussion and, if required, we
will consult the subject experts (WQ, SH).
Data extraction and management
We will design a data extraction form. Three review authors (KN,
BA, SA) will independently extract the data using the agreed upon
form. We will resolve discrepancies through discussion and, if re-
quired, we will consult the subject experts (WQ, SH). We will
enter the data into the ReviewManager software (Revman 2011)
and check for accuracy.
Assessment of risk of bias in included studies
Three review authors (KN, BA, SA) will independently assess
the risk of bias for each study using the criteria outlined in the
Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011a). We will resolve any disagreement by discussion
with the subject experts (WQ, SH).
The following criteria will be assessed:
• was the allocation sequence adequately generated?
• was the allocation adequately concealed?
• was knowledge of the allocated intervention adequately pre-
vented during the study?
• were incomplete outcome data adequately addressed?
• were reports of the study free of suggestion of selective outcome
reporting?
• was the study apparently free of other problems that could put
it at a high risk of bias?
A judgement of ‘Yes’ indicates low risk of bias, ‘No’ indicates high
risk of bias and ‘Unclear’ indicates unclear or unknown risk of
bias. Interrater agreement for key bias indicators (e.g. allocation
concealment, incomplete outcome data) will be calculated using
the kappa statistic (Cohen 1960). In cases of disagreement, mem-
bers of the research team will be consulted and a judgement will
be made based on consensus. We will produce a risk of bias graph
and risk of bias summary figure. Primary analyses for the review
will be conducted including only those trials judged to be of ’low’
risk of bias, considering all domains analysed. Domains relating to
randomisation (sequence generation and allocation concealment)
and blinding of participants, personnel and outcome assessors are
likely to have the largest impact on bias in experimental studies. If
adequate data are available, we will assess the impact of individual
bias domains on study results. A sensitivity analysis including all
studies will be performed to determine the impact that potentially
high risk of bias studies may have had on the conclusions of the
review.
Measures of treatment effect
Dichotomous outcomes will be expressed as risk ratio (RR) with
95% confidence intervals (CI). Continuous outcomes will be ex-
pressed as differences in means (MD) with 95% CI.
Unit of analysis issues
If any trials have multiple treatment groups, the ‘shared’ compari-
son groupwill be divided into the number of treatment groups and
comparisons between each treatment group and the split compari-
son group will be treated as independent comparisons. Cross-over
trials will be included if data from the first period are available.
Dealing with missing data
If feasible, we will obtain relevant missing data from authors, and
carefully perform evaluation of important numerical data such as
screened, randomised patients as well as intention-to-treat (ITT),
as-treated and per-protocol (PP) populations. We will investigate
attrition rates, for example drop-outs, losses to follow up and
withdrawals and critically appraise issues of missing data and im-
putation methods (for example last-observation-carried-forward
(LOCF)).
Assessment of heterogeneity
We will measure heterogeneity among the trials by calculating
the I2 statistic (Higgins 2002; Higgins 2003), which quantifies
inconsistency across studies to assess the impact of heterogeneity
on the meta-analysis. If the I2 statistic exceeds 50%, and the P
value for the Chi2 statistic is less than or equal to 0.1, and visual
inspection of the forest plots is indicative, then we will consider
heterogeneity to be substantial.
When heterogeneity is found, we will attempt to determine po-
tential reasons for it by examining individual study and subgroup
characteristics (Higgins 2011b).
Assessment of reporting biases
If there are an appropriate number of studies we will use funnel
plots to assess for the potential existence of small study bias. There
are a number of explanations for the asymmetry of a funnel plot
(Sterne 2001) and we will carefully interpret results (Lau 2006).
Data synthesis
Data will be pooled formeta-analysis if patients, interventions and
outcomes are comparable (based on author consensus). A fixed-
effect model will be used to pool data in the absence of hetero-
geneity. A random-effects model will be used to pool data when
moderate heterogeneity is identified, Data will not be pooled for
meta-analysis in cases where substantial heterogeneity is identified.
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Subgroup analysis and investigation of heterogeneity
If sufficient data are available subgroup analyses will be performed
to explore potential explanations for heterogeneity and to explore
the effects of: age (e.g. middle aged adults versus elderly), dose of
fibre/bulking agents and type of agents.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size:
• Repeating the analysis taking risk of bias, as specified above,
into account;
• Repeating the analysis excluding very long or large studies
to establish how much they influence the results; and
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
We will also test the robustness of the results by repeating the
analysis using different measures of effect size (relative risk, odds
ratio etc.) and different statistical models (fixed-effect model and
random-effects model).
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